source
- Capricor’s regulatory odyssey for DMD cell therapy hits second FDA rejectionA new proposed indication was not enough to get deramiocel across the regulatory finish line. The FDA has again turned away the cell therapy, which is being developed for Duchenne muscular dystroph…BioSpace · 58m ago↗ source
- RevMed's Rasonque shows strong first-line response and survival benefit in early pancreatic cancer dataRevMed reported early-stage results from its open‑label Phase 1/2 RMC‑GI‑102 trial, presented at the EORTC‑N conference, evaluating Rasonque combined with chemotherapy in patients with first‑line m…